# Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer

> **NCT01683994** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 49 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Docetaxel
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01683994
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-07
- **Primary completion:** 2018-07-01
- **Final completion:** 2019-01-16
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2019-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01683994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01683994, "Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01683994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*